Epimedium Effects on Alzheimer's Disease: Transcriptomic and In Vivo Study Data

172 key targets were identified through bioinformatic screening of Epimedium constituents against Alzheimer's disease. The dataset, authored by Jie Gao and last updated in April 2026, contains results from an in vivo rat model assessing cognitive function, histopathology, and cytokine levels, supporting the herb's potential therapeutic mechanism via KAT2B.

Use Cases

• Validate bioinformatic predictions of herb-target interactions based on the 172 identified key targets.
• Analyze correlations between cognitive performance (Morris water maze) and neuroinflammatory markers (IL-1β, TNF-α) in the animal model.
• Investigate the role of core genes KAT2B and ACACB in Alzheimer's disease pathology using the provided transcriptomic screening results.
• Compare histopathological changes in hippocampal neurons (H&E staining) across treatment and control groups.

Strengths

• Data integrates bioinformatic predictions (172 targets) with in vivo experimental validation.
• Includes multiple assay types: behavioral (Morris water maze), histological (H&E), and molecular (ELISA, qRT-PCR).
• Released under a permissive CC-BY-4.0 license, facilitating reuse and redistribution.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (168.9 KB), indicating limited scope or a summary of results rather than raw experimental data.

Provenance

Source

figshare, author Jie Gao.

Collection Method

Combined bioinformatic screening (TCMSP, PubChem, SwissTargetPrediction, GeneCards, OMIM, GEO) and in vivo rat model experiments.

Time Range

null

Freshness

Last updated 2026-04-20 04:12:08; freshness should be verified.

Geography

null